blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3877382

EP3877382 - NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  13.08.2021
Database last updated on 02.07.2024
FormerThe international publication has been made
Status updated on  16.05.2020
Most recent event   Tooltip22.12.2023Change - applicantpublished on 24.01.2024  [2024/04]
Applicant(s)For all designated states
Tianli Biotech Pty Ltd
Level 1, 401 Nancy Millis Building
Melbourne, VIC 3010 / AU
[2024/04]
Former [2021/37]For all designated states
The University of Melbourne
Grattan Street The University of Melbourne
Victoria 3010 / AU
Inventor(s)01 / STEWART, Alastair
c/- The University of Melbourne,
Intellectual Property & Licences
Research
Innovation & Commercialisation
The University of Melbourne, Victoria 3010 / AU
02 / WILLIAMS, Spencer
c/- The University of Melbourne,
Intellectual Property & Licences
Research
Innovation & Commercialisation
The University of Melbourne, Victoria 3010 / AU
03 / HAKKI, Zalihe
c/- The University of Melbourne,
Intellectual Property & Licences
Research
Innovation & Commercialisation
The University of Melbourne, Victoria 3010 / AU
 [2021/37]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2021/37]HGF
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date19881903.907.11.2019
[2021/37]
WO2019AU51225
Priority number, dateAU2018090424107.11.2018         Original published format: AU 2018904241
AU2018090424207.11.2018         Original published format: AU 2018904242
[2021/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020093098
Date:14.05.2020
Language:EN
[2020/20]
Type: A1 Application with search report 
No.:EP3877382
Date:15.09.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 14.05.2020 takes the place of the publication of the European patent application.
[2021/37]
Search report(s)International search report - published on:AU14.05.2020
(Supplementary) European search report - dispatched on:EP24.06.2022
ClassificationIPC:C07D405/14, C07D401/04, C07D403/04, C07D409/14, C07D401/14, A61K31/506, A61P11/00
[2022/30]
CPC:
C07D403/04 (EP,AU,US); C07D405/14 (EP,AU,US); A61P11/00 (EP,AU,US);
A61P11/06 (AU); C07D401/04 (AU); C07D401/14 (EP,AU);
C07D403/14 (US); C07D409/14 (EP,AU,US); C07B2200/05 (US) (-)
Former IPC [2021/37]C07D405/14, C07D401/04, C07D403/04, A61K31/506, A61P11/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/37]
TitleGerman:NEUARTIGE VERBINDUNGEN ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN[2021/37]
English:NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES[2021/37]
French:NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES[2021/37]
Entry into regional phase24.05.2021National basic fee paid 
24.05.2021Search fee paid 
24.05.2021Designation fee(s) paid 
24.05.2021Examination fee paid 
Examination procedure24.05.2021Examination requested  [2021/37]
12.01.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
24.11.2021Renewal fee patent year 03
24.11.2022Renewal fee patent year 04
24.11.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US5670527  (ADAMS JERRY LEROY [US], et al) [X] 15* RN Nr: 187217-96-5, 165-806-48-4,165806-50-8,165806-51-9,165806-79-1,165806-82-6,187217-97-6; column 1, line 11 - column 1, line 15 *;
 [X]WO9918942  (IMP COLLEGE INNOVATIONS LTD [GB], et al) [X] 15 * RN Nr. 1656806-48-4, 165806-50-8,165806-51-9, 165806-79-1,165806-82-6,220654-11-5; page 1, line 7 - page 1, line 8 *;
 [X]US2011098272  (SUBRAMANYAM CHAKRAPANI [US], et al) [X] 15 * paragraph [0001]; examples 1,3,4,17-30,32-38 *;
 [X]  - BING-KE LI ET AL, "In silico prediction of spleen tyrosine kinase inhibitors using machine learning approaches and an optimized molecular descriptor subset generated by recursive feature elimination method", COMPUTERS IN BIOLOGY AND MEDICINE, (20130501), vol. 43, no. 4, doi:10.1016/j.compbiomed.2013.01.015, ISSN 0010-4825, pages 395 - 404, XP055143456 [X] 1-5,10,14 * RN:1551022-37-7 *

DOI:   http://dx.doi.org/10.1016/j.compbiomed.2013.01.015
 [X]  - RUDOLPH JOHANNES ET AL, "Slow Inhibition and Conformation Selective Properties of Extracellular Signal-Regulated Kinase 1 and 2 Inhibitors", BIOCHEMISTRY, (20150113), vol. 54, no. 1, doi:10.1021/bi501101v, ISSN 0006-2960, pages 22 - 31, XP055929434 [X] 15 * abstract; table 1, compound SB220025 *

DOI:   http://dx.doi.org/10.1021/bi501101v
 [X]  - TRAVIS T. WAGER ET AL, "Casein Kinase 1delta/epsilon Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior", ACS CHEMICAL NEUROSCIENCE, US, (20141028), vol. 5, no. 12, doi:10.1021/cn500201x, ISSN 1948-7193, pages 1253 - 1265, XP055747252 [X] 15 * tabel 1, compounds 1-7 *

DOI:   http://dx.doi.org/10.1021/cn500201x
 [X]  - F R Pinsetta ET AL, "Send Orders of Reprints at [email protected] Rational Design of Novel Potential p38 MAPK Inhibitors with Drug-like Properties Using Pharmacophore and Similarity-based Virtual Screening Procedures", (20130301), URL: http://72.167.252.165/download.php?param=Sk9VnUk5zBTFeMvQjkVO1L0NfCQyx85LpzEveRDArwMDuJCQpy5woZGZl8fG3FwckGxpuY2Fk0aW39uLt3Bk7Znxw8YWEM0OCWY02OTdzjMz6RlYxjgwkYjYp2OD6ExZdjdhENmVAjZjnk1YdzQTcVYv&key=QVhFAaWRtFLUzVJQ7TMytRDMu1RjectNjDMygLTIpzNDjMyMC0RHxZUQ4TcVY, (20140715), XP055128951 [X] 15 * figure 3, compounds IBMK,IBL7 *
 [X]  - NATALIE B VINH ET AL, "Virtual screening using a conformationally flexible target protein: models for ligand binding to p38Î MAPK", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, KLUWER ACADEMIC PUBLISHERS, DO, (20120420), vol. 26, no. 4, doi:10.1007/S10822-012-9569-7, ISSN 1573-4951, pages 409 - 423, XP035053360 [X] 15 * abstract; figure 3, compounds SB218655, SB220025, SB216385, 1-18 *

DOI:   http://dx.doi.org/10.1007/s10822-012-9569-7
International search[X]WO9621654  (SMITHKLINE BEECHAM CORP [US], et al) [X] 1-32, 34-36 * examples on pages 11, lines 3-11, page 12, lines 1-4, lines 33-38; page 32, compounds 5 to 9; page 33, compound 10, page 37, lines 17 to 19; page 38, line 22; claims 1, 13, 19 *;
 [X]US5593992  (ADAMS JERRY L [US], et al) [X] 1-32, 34-36 * col 11, lines 58-59, lines 62-63, lines 64-65, col 12, lines 58-59, claims 1, 11, 14 and 28 *;
 [A]WO9735856  (SMITHKLINE BEECHAM CORP [US], et al) [A] 1-32, 34-36 * page 15, lines 19, 21, 22; page 16, line 21, 25, 28; page 17, line 31, 33, 34, 35; page 18, lines 3, 30, 32; page 19, line 25, 27 and 29 *;
 [X]WO9901136  (SMITHKLINE BEECHAM CORP [US], et al) [X] 1-32, 34-36 * examples, claims 1, 9, 10, 13 *;
 [X]WO9932121  (SMITHKLINE BEECHAM CORP [US], et al) [X] 1-32, 34-36 * page 19, Table, 2nd, 3rd, 4th, 5th, 6th and 8th compounds, page 20, Table, 1st compound; page 21, Table, 2nd and 3rd compounds; page 22, Table, 1st, 2nd , 3rd, 5th and 6th compounds, examples, page 30, line 32 and 35; page 32, lines 10-12; page 33, lines 14-15; claims 4, 10, page 26, line 25 to page 28, line 29 *;
 [A]US6369068  (ADAMS JERRY LEROY [US], et al) [A] 1-32, 34-36 * col 7, lines 8-33, Examples *;
 [X]WO2016149756  (UNIV MELBOURNE [AU]) [X] 35 * claims 5 and 6, second compound, claims 7 to 21 *;
 [XP]WO2018201192  (UNIV MELBOURNE [AU]) [XP] 1-32, 34-36* Formula (I), Figure 8, compound 184, Abstract, page 57, compounds 13, 16, 19, 22, 25, 28, 31, 34, 37, 43, 14, 17, 20, 23, 26, 29, 32, 35, 38, 44; page 72, compounds 47, 48; page 74, compounds 51, 52, page 77, compound 55; page 79, compounds 73, 74, 75; page 87, compounds 81, 82, 83, 84; page 91, compounds 86, 87, 89, 90 *;
 [X]  - KEENAN, C. R. et al., "Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis", Frontiers in Pharmacology, (20180700), vol. 9, page 738, XP055707234 [X] 35 * . the whole document and Title, Introdcution *

DOI:   http://dx.doi.org/10.3389/fphar.2018.00738
 [A]  - KIM, D-K. et al., "Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38a mitogen-activated protein kinase", Bioorganic & Medicinal Chemistry Letters, (20080000), vol. 18, no. 14, doi:10.1016/j.bmcl.2008.06.007, pages 4006 - 4010, XP022852885 [A] 1-32, 34-36 * page 4008, compounds 20a, 20b, 20c, 20d, 21a, 22a, 22b, 22c, 23a, Table 1 *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2008.06.007
 [X]  - CAS, (20111205), Database accession no. 1349012-04-9, URL: STN [X] 1-3, 7-9, 20-21, 23-25 * ; 2-Pyrimidinamine, N-(3-[1,1'-biphenyl]-3-ylpropyl)-4-[1-cyclohexyl-4-(4- fluorophenyl)-1H-imidazol-5-yl]-the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.